US Patent

US10828294 — Compositions and methods for weight loss in at risk patient populations

Method of Use · Assigned to Nalpropion Pharmaceuticals LLC · Expires 2034-07-02 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating overweight or obese subjects at increased risk of adverse cardiovascular outcomes using naltrexone plus bupropion.

USPTO Abstract

The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1583`	—

Patent Metadata

Patent number: US10828294
Jurisdiction: US
Classification: Method of Use
Expires: 2034-07-02
Drug substance claim: No
Drug product claim: No
Assignee: Nalpropion Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.